Induced Pluripotent Stem Cell Technology Heralds a New Era in Drug Discovery
Scientists and clinicians agree that human stem cells hold enormous potential to revolutionize the treatment of diseases. iPierian’s technology will unleash this potential by generating pluripotent stem cells from patients to study and battle diseases in ways never before possible. The company is developing and applying cellular reprogramming and differentiation technologies to harness the power of pluripotent stem cells to transform drug discovery and enable the promise of regenerative medicine. iPierian's induced pluripotent stem (iPS) cell technology will advance the understanding of disease biology and make drug discovery and development faster and better informed.
iPierian plans to apply this revolutionary technology in its proprietary programs and leverage it in collaborations with pharmaceutical and biotechnology industry partners. The company's reprogramming and differentiation technologies will enable the identification of promising new therapeutic candidates earlier in the drug discovery process. Through its efforts, iPierian expects to make pharmaceutical research more directly beneficial to patients and more cost-effective for its partners.
